C4 Therapeutics, Inc.’s Post

#KeiretsuBacked Aprea to share insights on optimizing patient selection for DDR inhibitor combinations at the 2024 DDR Inhibitors Summit. As leaders in precision oncology through synthetic lethality, the company will discuss defining clinical success for current and next-gen DDR therapies. Learn more: https://bit.ly/3StLAZ9 #Aprea #DDRInhibitorsSummit #PrecisionOncology #SyntheticLethality #ClinicalSuccess #OncologyResearch

Lots of interest in this target for both diagnostic imaging and therapeutic applications.

Tumor-agnostic drug development in dMMR/MSI-H solid tumors: Trends in Cancer https://ow.ly/2Gwa50Q0a4o

Interested to hear the latest in #PrecisionOncology? Hear from Dr. Kyle Strickland and Dr. Rebecca Previs as they discuss the different components of liquid biopsy and current technologies used to isolate circulating tumor cells (CTCs) and cell-free DNA (cfDNA). In this webinar, you will learn the potential clinical implications of liquid biopsies on molecular profiling of tumors for therapy selection, early detection of cancer, drug response and therapy resistance. Watch the video to learn more.

Standard setting is the comprehensive and systemic process through which an examination's passing score is set. In this article, authors analyze the standard setting process for the ABS Complex General Surgical Oncology Qualifying Examination - https://ow.ly/QFBw50R4AQ2

Join Beth Rodriguez at #SCOPE2024 for a lunch presentation tomorrow, February 13, at 12:50 pm about successful outsourcing in late-phase CNS and oncology imaging trials! Explore factors such as where partnerships may falter, tips for optimizing collaborations, and understanding the therapeutic area's size and scope of projects. This session promises to reshape your approach to late-phase CNS and Oncology imaging trials, from unraveling imaging CROs to navigating processes for start-ups. #SCOPEsummit #imagingCRO

Interested to hear the latest in #PrecisionOncology? Hear from Dr. Kyle Strickland and Dr. Rebecca Previs as they discuss the different components of liquid biopsy and current technologies used to isolate circulating tumor cells (CTCs) and cell-free DNA (cfDNA). In this webinar, you will learn the potential clinical implications of liquid biopsies on molecular profiling of tumors for therapy selection, early detection of cancer, drug response and therapy resistance. Watch the video to learn more.

Interested to hear the latest in #PrecisionOncology? Hear from Dr. Kyle Strickland and Dr. Rebecca Previs as they discuss the different components of liquid biopsy and current technologies used to isolate circulating tumor cells (CTCs) and cell-free DNA (cfDNA). In this webinar, you will learn the potential clinical implications of liquid biopsies on molecular profiling of tumors for therapy selection, early detection of cancer, drug response and therapy resistance. Watch the video to learn more.

Interested to hear the latest in #PrecisionOncology? Hear from Dr. Kyle Strickland and Dr. Rebecca Previs as they discuss the different components of liquid biopsy and current technologies used to isolate circulating tumor cells (CTCs) and cell-free DNA (cfDNA). In this webinar, you will learn the potential clinical implications of liquid biopsies on molecular profiling of tumors for therapy selection, early detection of cancer, drug response and therapy resistance. Watch the video to learn more.

Interested to hear the latest in #PrecisionOncology? Hear from Dr. Kyle Strickland and Dr. Rebecca Previs as they discuss the different components of liquid biopsy and current technologies used to isolate circulating tumor cells (CTCs) and cell-free DNA (cfDNA). In this webinar, you will learn the potential clinical implications of liquid biopsies on molecular profiling of tumors for therapy selection, early detection of cancer, drug response and therapy resistance. Watch the video to learn more.